Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The End Of The FDA Approvals Boom? Fewer Applications Are A COVID-19 Consequence

Executive Summary

Applications for US FDA approval are lower than in recent history, portending a lean 2021.

You may also be interested in...



Keeping Track: Biogen’s Aducanumab Headlines Midsummer Submission Round-Up

The latest application submission news and highlights from the Pink Sheet’s US FDA Performance Tracker.

US FDA Not Missing Assessment Goals, But Guidance Reminds That It’s Possible

New Q&A guidance also states that its near-term focus for resources will be on coronavirus and some other conditions.

Keeping Track Of Submissions: Myovant’s First Relugolix NDA; Merck Resubmits Longer Keytruda Dosing; Biogen Adjusts Aducanumab Rolling Target

The latest news and highlights about submissions for US approval, from the Pink Sheet FDA Performance Tracker.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS142425

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel